Global Lung Cancer Genomic Testing Market Growth (Status and Outlook) 2023-2029

Global Lung Cancer Genomic Testing Market Growth (Status and Outlook) 2023-2029

The global Lung Cancer Genomic Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Lung Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Lung Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Lung Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Lung Cancer Genomic Testing players cover CD Genomics, Qiagen NV, Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Agilent Technologies Inc., Illumina Inc., Thermo Fischer Scientific Inc., Abbott Laboratories Inc. and Quest Diagnostics Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Lung Cancer Genomic Testing Industry Forecast” looks at past sales and reviews total world Lung Cancer Genomic Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Lung Cancer Genomic Testing sales for 2023 through 2029. With Lung Cancer Genomic Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lung Cancer Genomic Testing industry.

This Insight Report provides a comprehensive analysis of the global Lung Cancer Genomic Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lung Cancer Genomic Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lung Cancer Genomic Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lung Cancer Genomic Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lung Cancer Genomic Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of Lung Cancer Genomic Testing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Liquid Biopsy
Tissue Biopsy

Segmentation by application
Hospitals/Clinics
Research Organization
Diagnostic Laboratories

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CD Genomics
Qiagen NV
Laboratory Corporation of America Holdings
NeoGenomics Laboratories
Agilent Technologies Inc.
Illumina Inc.
Thermo Fischer Scientific Inc.
Abbott Laboratories Inc.
Quest Diagnostics Inc.
OncoDNA
Centogene N.V.
Admera Health
CeGaT GmbH
OPKO Health Inc.
F. Hoffmann-La Roche AG.



Please note: The report will take approximately 2 business days to prepare and deliver.